{
    "clinical_study": {
        "@rank": "45224", 
        "arm_group": {
            "arm_group_label": "Treatment (desipramine, filgrastim)", 
            "arm_group_type": "Experimental", 
            "description": "Patients receive desipramine hydrochloride PO daily on days -3 to +4 and filgrastim PO BID on days 1-4. Stem cell collection begins on day 6."
        }, 
        "brief_summary": {
            "textblock": "This pilot clinical trial studies how well desipramine hydrochloride and filgrastim works\n      for stem cell mobilization in patients with multiple myeloma undergoing stem cell\n      transplant. Giving colony-stimulating factors, such as filgrastim, and other drugs, such as\n      desipramine hydrochloride, helps stem cells move from the patient's bone marrow to the blood\n      so they can be collected and stored."
        }, 
        "brief_title": "Desipramine Hydrochloride and Filgrastim For Stem Cell Mobilization in Patients With Multiple Myeloma Undergoing Stem Cell Transplant", 
        "condition": [
            "Refractory Multiple Myeloma", 
            "Stage I Multiple Myeloma", 
            "Stage II Multiple Myeloma", 
            "Stage III Multiple Myeloma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Multiple Myeloma", 
                "Neoplasms, Plasma Cell"
            ]
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. To study efficacy, safety, harvest kinetics and engraftment kinetics of patients\n      undergoing autologous stem cell mobilization, mobilized with a combination of granulocyte\n      colony-stimulating factor (GCSF) (filgrastim) with desipramine (desipramine hydrochloride)\n      (G+D).\n\n      II. To analyze polymorphisms of adrenergic receptor beta 2 (ADRB2) and adrenergic receptor\n      beta 3 (ADRB3) genes that correlate with mobilization efficiency.\n\n      OUTLINE:\n\n      Patients receive desipramine hydrochloride orally (PO) daily on days -3 to +4 and filgrastim\n      PO twice daily (BID) on days 1-4. Stem cell collection begins on day 6.\n\n      After completion of study treatment, patients are followed up 1 week after completion of\n      stem cell collection."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients eligible for autologous stem cell transplant for multiple myeloma; planned\n             use of filgrastim (GCSF) for stem cell mobilization\n\n          -  Ability to give informed consent\n\n          -  Glomerular filtration rate (GFR) > 30 ml/minute\n\n          -  Liver function tests < 2.5 x upper limit of normal (ULN)\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) 2 or less\n\n          -  Based on prior therapy patients will be classified into two categories:\n\n               -  Initial mobilizers with no exposure to alkylators\n\n               -  Remobilizers or with prior exposure to alkylators or with greater than 5 cycles\n                  of lenalidomide therapy prior to mobilization\n\n        Exclusion Criteria:\n\n          -  Use of a monoamine oxidase inhibitor (MAO-I) during or within 2 weeks of desipramine\n             therapy\n\n          -  Concomitant therapy with any drugs shown to have major interactions with desipramine\n\n          -  Concurrent use of drugs that are contraindicated with desipramine\n\n          -  Myocardial infarction in preceding 4 weeks; history of uncontrolled cardiac\n             arrhythmias or family history of sudden cardiac death; baseline corrected QT (QTc) >\n             460 msec\n\n          -  Active alcohol abuse\n\n          -  Bipolar disorder\n\n          -  Untreated active major depression\n\n          -  History of seizures in the past 3 years\n\n          -  Pregnancy and lactation; refusal to use adequate contraception\n\n          -  Uncontrolled thyroid disease\n\n          -  GCSF or pegfilgrastim use within 14 days prior to enrollment\n\n          -  Bortezomib, revlimid or thalidomide use within 7 days of enrollment\n\n          -  Patients with sickle cell disease"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01899326", 
            "org_study_id": "2012-230", 
            "secondary_id": [
                "NCI-2013-01212", 
                "11-010", 
                "2012-230", 
                "P30CA013330"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Treatment (desipramine, filgrastim)", 
                "description": "Given PO", 
                "intervention_name": "desipramine hydrochloride", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Norpramin", 
                    "Pertofrane"
                ]
            }, 
            {
                "arm_group_label": "Treatment (desipramine, filgrastim)", 
                "description": "Given PO", 
                "intervention_name": "filgrastim", 
                "intervention_type": "Biological", 
                "other_name": [
                    "G-CSF", 
                    "Neupogen"
                ]
            }, 
            {
                "arm_group_label": "Treatment (desipramine, filgrastim)", 
                "description": "Correlative studies", 
                "intervention_name": "laboratory biomarker analysis", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Desipramine", 
                "Lenograstim"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 2, 2014", 
        "location": {
            "contact": {
                "email": "MJANAKIR@montefiore.org", 
                "last_name": "Murali Janakiram", 
                "phone": "718-920-4826"
            }, 
            "contact_backup": {
                "email": "MMIRANDE@montefiore.org", 
                "last_name": "Markenya Mirander", 
                "phone": "718-379-6863"
            }, 
            "facility": {
                "address": {
                    "city": "Bronx", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10461"
                }, 
                "name": "Albert Einstein College of Medicine/Montefiore Medical Center"
            }, 
            "investigator": {
                "last_name": "Murali Janakiram", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Pilot Clinical Study of GCSF in Combination With Desipramine for Autologous Stem Cell Mobilization in Multiple Myeloma", 
        "overall_official": {
            "affiliation": "Albert Einstein College of Medicine of Yeshiva University", 
            "last_name": "Murali Janakiram", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Standard descriptive statistics will be used to summarize the data, including means, medians, standard deviations and ranges for continuous variables, and frequencies for categorical variables. The success rates observed in first-time mobilizers, along with corresponding 95% binomial confidence intervals, will be estimated.", 
                "measure": "Success rate of stem cell mobilization (SCM) using filgrastim and desipramine to collect > 5 x 10^6 cluster of differentiation (CD)34/kg in patients with multiple myeloma (MM) who are first time mobilizers or unexposed to alkylating agents", 
                "safety_issue": "No", 
                "time_frame": "Day 5"
            }, 
            {
                "description": "Standard descriptive statistics will be used to summarize the data, including means, medians, standard deviations and ranges for continuous variables, and frequencies for categorical variables. The success rates observed in predicted difficult mobilizers, along with corresponding 95% binomial confidence intervals, will be estimated.", 
                "measure": "Success rate of SCM using filgrastim and desipramine to achieve a total collection of > 5 x 10^6 CD34/kg in patients with MM who failed prior mobilization or were exposed to alkylator therapy or are predicted to be difficult to mobilize", 
                "safety_issue": "No", 
                "time_frame": "Day 5"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01899326"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Albert Einstein College of Medicine of Yeshiva University", 
            "investigator_full_name": "Murali Janakiram", 
            "investigator_title": "Principal Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Standard descriptive statistics will be used to summarize the data, including means, medians, standard deviations and ranges for continuous variables, and frequencies for categorical variables.", 
                "measure": "Average number of days of apheresis required to collect > 5 x 10^6 CD34+/kg", 
                "safety_issue": "No", 
                "time_frame": "Up to 1 week after completion of study treatment"
            }, 
            {
                "description": "Standard descriptive statistics will be used to summarize the data, including means, medians, standard deviations and ranges for continuous variables, and frequencies for categorical variables.", 
                "measure": "Incidence of adverse events graded by the National Cancer Institute Common Terminology Criteria for Adverse Events version 4", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 1 week after completion of study treatment"
            }, 
            {
                "description": "Standard descriptive statistics will be used to summarize the data, including means, medians, standard deviations and ranges for continuous variables, and frequencies for categorical variables.", 
                "measure": "Time to neutrophil engraftment: first of three consecutive days with absolute neutrophil count (ANC) > 500/ul or first day with ANC > 1000/ul in the absence of growth factor support", 
                "safety_issue": "No", 
                "time_frame": "Up to 1 week after completion of study treatment"
            }, 
            {
                "description": "Standard descriptive statistics will be used to summarize the data, including means, medians, standard deviations and ranges for continuous variables, and frequencies for categorical variables.", 
                "measure": "Time to platelet engraftment: first of three days of platelets > 20,000/ul without transfusion", 
                "safety_issue": "No", 
                "time_frame": "Up to 1 week after completion of study treatment"
            }
        ], 
        "source": "Albert Einstein College of Medicine of Yeshiva University", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "National Cancer Institute (NCI)", 
                    "agency_class": "NIH"
                }, 
                {
                    "agency": "Montefiore Medical Center", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Albert Einstein College of Medicine of Yeshiva University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}